Suven Life Sciences (SUVEN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Suven Life Sciences (SUVEN) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹7,190 Crore, trading at ₹319.15 on the BSE. This SniperIQ fundamentals page covers Suven Life Sciences's valuation, profitability (net margin -3884.1%), revenue (₹7 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Suven Life Sciences's market cap?
Suven Life Sciences (SUVEN) has a market capitalization of approximately ₹7,190 Crore, trading at ₹319.15 on the BSE. Market cap moves with the live share price.
What is Suven Life Sciences's P/E ratio?
Suven Life Sciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 12.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Suven Life Sciences?
Suven Life Sciences runs a net profit margin of -3884.1%, a gross margin of -413.7%, and an operating margin of -4077.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Suven Life Sciences generate?
Suven Life Sciences reported revenue of ₹7 Crore for fiscal year 2026, with net income of -₹276 Crore and earnings per share (EPS) of -12.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Suven Life Sciences pay a dividend?
Suven Life Sciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Suven Life Sciences financially healthy?
Suven Life Sciences carries a debt-to-equity ratio of 0.03x and a current ratio of 17.69x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Suven Life Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Suven Life Sciences (SUVEN) the key facts are: market cap ₹7,190 Crore, revenue ₹7 Crore, 52-week range 102.7-342.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Suven Life Sciences's full fundamentals live
Get Suven Life Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.